CyDex Pharmaceuticals
San Diego · Founded 1993
About CyDex Pharmaceuticals
CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company's products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007. The company was founded in 1993 and is based in Lenexa, Kansas.
Company Facts
- Founded: 1993
- Legal name: CyDex Pharmaceuticals Inc
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Website: captisol.com
- Phone: 877-575-5593
Social Profiles
Canonical: https://fsome.com/organization/cydex-pharmaceuticals-8392557 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.